CAMBRIDGE, Mass., Sept. 6,
2022 /PRNewswire/ -- Omega Therapeutics, Inc.
(NASDAQ: OMGA) ("Omega"), a clinical-stage biotechnology company
pioneering the first systematic approach to use mRNA therapeutics
as a new class of programmable epigenetic medicines by leveraging
its OMEGA Epigenomic Programming™ platform, today announced that
management will participate in a fireside chat at the H.C.
Wainwright 24th Annual Global Investment Conference on
Monday, September 12, 2022, at
10 a.m. ET.
A live webcast of the fireside chat will be available on the
Investors & Media section of the Company's website at
www.omegatherapeutics.com. An archived replay of the fireside chat
will be available on the same website for approximately 90
days.
About Omega Therapeutics
Omega Therapeutics, founded by Flagship Pioneering, is a
clinical-stage biotechnology company pioneering the first
systematic approach to use mRNA therapeutics as a new class of
programmable epigenetic medicines. The company's OMEGA Epigenomic
Programming™ platform harnesses the power of epigenetics, the
mechanism that controls gene expression and every aspect of an
organism's life from cell genesis, growth, and differentiation to
cell death. Using a suite of technologies, paired with Omega's
process of systematic, rational, and integrative drug design, the
OMEGA platform enables control of fundamental epigenetic processes
to correct the root cause of disease by returning aberrant gene
expression to a normal range without altering native nucleic acid
sequences. Omega's modular and programmable mRNA medicines, Omega
Epigenomic Controllers™, are designed to target specific epigenomic
loci within insulated genomic domains, EpiZips, from amongst
thousands of unique, mapped, and validated genome-wide
DNA-sequences, with high specificity to durably tune single or
multiple genes to treat and cure diseases through Precision Genomic
Control™. Omega is currently advancing a broad pipeline of
development candidates spanning a range of disease areas, including
oncology, regenerative medicine, multigenic diseases including
immunology, and select monogenic diseases, including alopecia.
For more information, visit omegatherapeutics.com, or
follow us on Twitter and LinkedIn.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding our participation in upcoming events and presentations
and expectations regarding our business strategy and product
candidate pipeline, including efficacy, trial design, regulatory
submissions, approvals and timing thereof, and initiation of
preclinical studies and advancement of multiple preclinical
development programs. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
following: the novel technology on which our product candidates are
based makes it difficult to predict the time and cost of
preclinical and clinical development and subsequently obtaining
regulatory approval, if at all; the substantial development and
regulatory risks associated with epigenomic controller machines due
to the novel and unprecedented nature of this new category of
medicines; our limited operating history; the incurrence of
significant losses and the fact that we expect to continue to incur
significant additional losses for the foreseeable future; our need
for substantial additional financing; our investments in research
and development efforts that further enhance the OMEGA platform,
and their impact on our results; uncertainty regarding preclinical
development, especially for a new class of medicines such as
epigenomic controllers; the fact that our product candidates may be
associated with serious adverse events, undesirable side effects or
have other properties that could halt their regulatory development,
prevent their regulatory approval, limit their commercial
potential, or result in significant negative consequences; the
impact of increased demand for the manufacture of mRNA and LNP
based vaccines to treat COVID-19 on our development plans;
difficulties manufacturing the novel technology on which our OEC
candidates are based; our ability to adapt to rapid and significant
technological change; our reliance on third parties for the
manufacture of materials; our ability to successfully acquire and
establish our own manufacturing facilities and infrastructure; our
reliance on a limited number of suppliers for lipid excipients used
in our product candidates; our ability to advance our product
candidates to clinical development; and our ability to obtain,
maintain, enforce and adequately protect our intellectual property
rights. These and other important factors discussed under the
caption "Risk Factors" in our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2022 and our
other filings with the SEC could cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release. Any such forward-looking statements
represent management's estimates as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
Contacts
Media contact:
Jason
Braco
LifeSci Communications
646.751.4361
jbraco@lifescicomms.com
Investor contact:
Kevin
Murphy
Argot Partners
212.600.1902
ArgotOmega@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/omega-therapeutics-to-participate-in-the-hc-wainwright-24th-annual-global-investment-conference-301617171.html
SOURCE Omega Therapeutics